Remove 2024 Remove Hospitals Remove Insurance
article thumbnail

STAT+: UnitedHealth continues making stealthy deals, pushing deeper into medical care as scrutiny mounts

STAT

  The sprawling conglomerate — which owns a major health insurance company, physician practices, a pharmacy benefit manager, and numerous other firms — acquired or created more than 250 subsidiaries in 2024. UnitedHealth Group, the largest health care company in the U.S., has clear ambitions of getting bigger. 

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gabapentin overdose in dogs: Symptoms and prevention

The Checkup by Singlecare

According to a 2024 study in Animals, gabapentin is also safe and well-tolerated for dogs with behavior disorders. Toxicity depends on multiple things, such as the dose ingested, the dogs size, and overall health, adds Dr. Nita Vasudevan, DVM, a veterinarian and veterinary consultant for Embrace Pet Insurance.

Dosage 59
article thumbnail

The European Market Access Lag: 2021–2024

Pharmaceutical Technology

On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. First, the access landscape for 220 originator medicines approved by the EMA between 2021–2024 was assessed. Reimbursement status for each brand per European market was analysed during this period.

article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence.

article thumbnail

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid

Pharmaceutical Technology

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

FDA 52
article thumbnail

Vutrisiran marks first silencer approved for ATTR-CM

Pharmaceutical Technology

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.